Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes.

ABSTRACT:

Importance

Understanding cardiovascular outcomes of initiating second-line antidiabetic medications (ADMs) may help inform treatment decisions after metformin alone is not sufficient or not tolerated. To date, no studies have compared the cardiovascular effects of all major second-line ADMs during this early decision point in the pharmacologic management of type 2 diabetes.

Objective

To examine the association of second-line ADM classes with major adverse cardiovascular events.

Design, setting, and participants

Retrospective cohort study among 132 737 insured adults with type 2 diabetes who started therapy with a second-line ADM after taking either metformin alone or no prior ADM. This study used 2011-2015 US nationwide administrative claims data. Data analysis was pe

SUBMITTER: O'Brien MJ 

PROVIDER: S-EPMC6324353 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature